Genocea Biosciences, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2006-01-01

Employees: 74

Market Cap: -

Website: http://www.genocea.com

Clinical Trials

TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy

Phase 1

Terminated

Conditions: Melanoma
Non-small Cell Lung Cancer
Renal Cell Carcinoma
Small-cell Lung Cancer
Cutaneous Squamous Cell Carcinoma
Squamous Cell Carcinoma of Head and Neck
Urothelial Carcinoma
Anal Squamous Cell Carcinoma
Merkel Cell Carcinoma

Interventions: Biological: GEN-011
Drug: IL-2
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2020-10-22

Last Posted Date: 2022-07-15

Lead Sponsor: Genocea Biosciences, Inc.

Target Recruit Count: 49

Registration Number: NCT04596033

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 5 locations

Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

Phase 1

Completed

Conditions: Non-small Cell Lung Cancer
Urothelial Carcinoma
Squamous Cell Carcinoma of the Head and Neck
Cutaneous Melanoma
Renal Cell Carcinoma

Interventions: Biological: GEN-009 Adjuvanted Vaccine
Drug: Nivolumab
Drug: Pembrolizumab

First Posted Date: 2018-08-16

Last Posted Date: 2022-04-19

Lead Sponsor: Genocea Biosciences, Inc.

Target Recruit Count: 24

Registration Number: NCT03633110

Locations: 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
John Wayne Cancer Institute - Providence Saint John's Health Center, Santa Monica, California, United States
🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States

and more 8 locations

Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection

Phase 2

Terminated

Conditions: Genital Herpes
HSV-2 Infection

Interventions: Biological: GEN-003
Other: 0.9% normal saline
Biological: Matrix-M2

First Posted Date: 2017-05-09

Last Posted Date: 2019-02-19

Lead Sponsor: Genocea Biosciences, Inc.

Target Recruit Count: 33

Registration Number: NCT03146403

Locations: 🇺🇸
UNC Health, Chapel Hill, North Carolina, United States
🇺🇸
Tekton Research, Austin, Texas, United States
🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States

and more 5 locations

Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity

Completed

Conditions: Genital Herpes Simplex Type 2

First Posted Date: 2016-09-22

Last Posted Date: 2017-10-20

Lead Sponsor: Genocea Biosciences, Inc.

Target Recruit Count: 140

Registration Number: NCT02910284

Locations: 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸
Quest Clinical Research, San Francisco, California, United States
🇺🇸
University of Alabama - Birmingham, Birmingham, Alabama, United States

and more 10 locations

Evaluating New Formulation of Therapeutic HSV-2 Vaccine

Phase 2

Completed

Conditions: Genital Herpes Simplex Type 2

Interventions: Biological: Matrix-M2
Drug: Placebo
Biological: GEN-003

First Posted Date: 2015-08-04

Last Posted Date: 2018-05-22

Lead Sponsor: Genocea Biosciences, Inc.

Target Recruit Count: 131

Registration Number: NCT02515175

Locations: 🇺🇸
The Fenway Institute, Boston, Massachusetts, United States
🇺🇸
University of Washington, Seattle, Washington, United States
🇺🇸
Medical Center for Clinical Research, San Diego, California, United States

and more 5 locations

Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study

Phase 2

Completed

Conditions: Genital Herpes Simplex Type 2

Interventions: Biological: GEN-003 Vaccine (30μg of each antigen)
Biological: GEN-003 Vaccine (60μg of each antigen)
Biological: Matrix-M2 Adjuvant (25μg)
Biological: Matrix-M2 Adjuvant (75μg)
Biological: Matrix-M2 Adjuvant (50μg)

First Posted Date: 2014-11-24

Last Posted Date: 2017-10-16

Lead Sponsor: Genocea Biosciences, Inc.

Target Recruit Count: 37

Registration Number: NCT02300142

Locations: 🇺🇸
Tekton Research, Austin, Texas, United States
🇺🇸
Center for Clinical Studies, Houston, Texas, United States
🇺🇸
Center for Clinical Studies - Clear Lake/Webster, Webster, Texas, United States

and more 13 locations

Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae

Phase 2

Completed

Conditions: Pneumonia, Pneumococcal
Pneumococcal Infections

Interventions: Biological: GEN-004 with Aluminum Hydroxide Adjuvant
Biological: Placebo
Biological: Streptococcus pneumoniae inoculation

First Posted Date: 2014-04-17

Last Posted Date: 2018-04-06

Lead Sponsor: Genocea Biosciences, Inc.

Target Recruit Count: 98

Registration Number: NCT02116998

Locations: 🇬🇧
Royal Liverpool University Hospital, Liverpool School of Tropical Medicine, Liverpool, United Kingdom

Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine

Phase 2

Completed

Conditions: Genital Herpes Simplex Type 2

Interventions: Biological: GEN-003 Vaccine (30μg of each antigen)
Biological: GEN-003 Vaccine (60μg of each antigen)
Biological: Placebo
Biological: Matrix-M2 Adjuvant (25μg)
Biological: Matrix-M2 Adjuvant (50μg)
Biological: Matrix-M2 Adjuvant (75μg)

First Posted Date: 2014-04-15

Last Posted Date: 2017-10-16

Lead Sponsor: Genocea Biosciences, Inc.

Target Recruit Count: 310

Registration Number: NCT02114060

Locations: 🇺🇸
University of Illinois Department of Medicine, Chicago, Illinois, United States
🇺🇸
Center for Clinical Studies, Houston, Texas, United States
🇺🇸
UW Virology Research Clinic, Seattle, Washington, United States

and more 13 locations

Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine

Phase 1

Completed

Conditions: Streptococcus Pneumoniae

Interventions: Biological: Placebo
Biological: GEN-004 Low Dose
Biological: GEN-004 High Dose
Biological: GEN-004 Mid Dose
Biological: GEN-004 Low Dose + Adjuvant
Biological: GEN-004 High Dose + Adjuvant
Biological: GEN-004 Mid Dose + Adjuvant

First Posted Date: 2013-11-26

Last Posted Date: 2015-12-11

Lead Sponsor: Genocea Biosciences, Inc.

Target Recruit Count: 90

Registration Number: NCT01995617

Locations: 🇺🇸
Prism Research, Saint Paul, Minnesota, United States

Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine

Phase 1

Completed

Conditions: Genital Herpes Simplex Type 2

Interventions: Biological: Placebo
Biological: GEN-003 with Matrix M-2
Biological: GEN-003

First Posted Date: 2012-08-17

Last Posted Date: 2018-06-01

Lead Sponsor: Genocea Biosciences, Inc.

Target Recruit Count: 143

Registration Number: NCT01667341

Locations: 🇺🇸
Center for Clinical Studies - Houston, Houston, Texas, United States
🇺🇸
UW Virology Research Clinic, Seattle, Washington, United States
🇺🇸
University of Alabama Vaccine Research Unit, Birmingham, Alabama, United States

and more 4 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy